



THE POWER OF PARTNERSHIPS

2020 NTC GOES VIRTUAL

Date/Time	Special Activity		
Friday, September 18, 2020 – Friday, September 17, 2021	<p>Virtual Exhibit Hall</p> <p><i>Join our industry colleagues and partners in the inaugural 2020 NTC Exhibit Hall. Although we cannot replicate the face-to-face contact we have all come to appreciate in the in-person TB conference, the inclusion of the Virtual Exhibit Hall in this year's conference provides all with an opportunity to connect and learn from our partners. We anticipate interactive "booths" where new products, publications, activities, and videos are showcased. Additional, unique opportunities to engage with our partners will be incorporated and the Exhibit Hall booths will remain open throughout the year as access to the conference's educational content continues.</i></p>		
Date/Time	Presentation	Moderator	Presenters
Friday, September 18, 2020 TIME: 3:00-5:00 PM EST	<p>Public Health Response to a Pandemic: Utilizing TB as a Blueprint for Action and Response</p> <p><i>The World Health Organization has designated 2020 as the International Year of the Nurse! The inaugural session of the Virtual National TB Conference will recognize the significant role that public health nurses have contributed to healthcare and the goal of TB Elimination. Nurses, such as Florence Nightingale, laid the foundation that supports today's framework of public health-prevention programs across the country and around the world.</i></p> <p><i>The framework of TB nursing, and the skillsets of staff within the TB public health program, has contributed substantially to the public health response during the current COVID pandemic. This session will explore how we can continue to apply this blueprint for effective action and response to future public health emergencies.</i></p>	Maureen Murphy-Weiss	Alisa Haushalter



THE POWER OF PARTNERSHIPS

2020 NTC GOES VIRTUAL

<p>Wednesday, September 23, 2020 TIME: 3:00-5:00 PM EST</p>	<p>Treatment of Drug-resistant TB: MDR Guidelines Overview and Current Use of BPAL in the United States <i>The diagnosis and treatment of drug-resistant TB continues to challenge even the most experienced clinicians equipped with the latest tools and medications. In this session, we will delve into the latest knowledge on drug-resistant TB treatment. Together with the lead author, we will explore the scientific basis behind the 2019 clinical practice guidelines for treatment of drug-resistant TB, differentiate the US recommendations from those issued by WHO, and explore implications for clinical decision-making by our members. The so-called “BPAL” regimen offers hope for an effective all-oral and short regimen for drug-resistant TB, but experience in the United States is very limited. We will share what is currently known about the key drug in this regimen, Pretomanid, and early clinical experience on this largely unmarked path.</i></p>	<p>Masa Narita Lisa Armitige</p> <p>Q&A Panelists: Sapna Bamrah Morris Neela Goswami</p>	<p>Payam Nahid Barbara Seaworth Connie Haley</p>
<p>Friday, September 25, 2020 TIME: 3:00-5:00 PM EST</p>	<p>Drug-Resistant TB Roadmap: Directions, Detours, and Roundabouts <i>In the session, we will discuss the challenges of managing drug-resistant TB patients with regards to implementing the drug-resistant TB guidelines, medication management, procuring medications, infection control, isolation, contact investigations, and case management over the course of treatment.</i></p>	<p>Nadya Sabuwala Tracy Murphy</p>	<p>Diana Nilsen Paul Jensen Nadya Sabuwala</p>
<p>Wednesday, September 30, 2020 TIME: 3:00-5:00 PM EST</p>	<p>Awards Session</p>	<p>Julie Higashi Pete Dupree</p>	
<p>Wednesday, September 30, 2020 TIME: 9:00 PM EST</p>	<p>Virtual Social – Purple Rain</p>	<p>NTCA Leadership</p>	
<p>Friday, October 2, 2020 TIME: 3:00-5:00 PM EST</p>	<p>Virtual Poster Session</p>	<p>Diana Fortune</p>	



THE POWER OF PARTNERSHIPS

2020 NTC GOES VIRTUAL

<p>Wednesday, October 7, 2020 TIME: 3:00-5:00 PM EST</p>	<p>State of the Science on Tuberculosis <i>This session will feature presentations on recent innovations that have the potential to transform how TB is diagnosed and treated.</i></p> <p><i>TB in humans has a spectrum of phenotypes, from asymptomatic infection to subclinical and mild disease through to severe active TB disease. Historically, across the continuum of the infection and disease, our tools have dichotomized the status of a patient infected with M.tb as having latent infection or active disease. Two presentations will share the latest developments in TB science that challenge this traditional dichotomy and provide information on how the existence of a spectrum can be harnessed in public health. The first presentation will discuss the spectrum of TB immunology and the emergence of novel biomarkers for TB diagnosis and response to treatment and then consider vaccines and tools that predict progression to active TB. The second presentation will explore the evidence base behind and potential applications of stratified medicine principles for treatment of TB and then delineate how patient-centered approaches to defining shorter treatment regimens and for improving cure rates are feasible. A concept trial protocol under consideration by the CDC TB Trials Consortium will be presented for discussion.</i></p>	<p>John Jereb Max Salfinger</p>	<p>David Lewinsohn Payam Nahid</p>
---------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------	----------------------------------------



THE POWER OF PARTNERSHIPS

2020 NTC GOES VIRTUAL

<p>Friday, October 9, 2020 TIME: 3:00-5:00 PM EST</p>	<p>TB and COVID-19: Clinical and Programmatic Responses <i>Given the significant public health challenges presented by the COVID-19 pandemic and the strong response from TB programs to date, this session will highlight the experiences of several jurisdictions which have been significantly impacted. Although it is likely too early to present evidence-based impacts of the pandemic on our TB programs, we recognize the importance of early case studies to better understand the response and the potential programmatic and patient-level impacts. Emphasis in the presentations will be given to the overall epidemiology of COVID in the jurisdictions, the changes implemented by the TB programs to continue serving individuals and families impacted by TB, and data related to TB-COVID-19 co-infections.</i></p>	<p>Pete Dupree</p>	<p>Joseph Burzynski Sheldon Riklon Virginia "Jenna" Maturino Thomas Dobbs</p>
<p>Wednesday, October 14, 2020 TIME: 3:00-5:00 PM EST</p>	<p>TB Screening, Testing, and Treatment of US Health Care Personnel Recommendations: Implementation Challenges & Opportunities <i>Implementation of the new paradigm for TB screening and testing for health care personnel (HCP) may present unique challenges in different settings. After a brief overview of the collaboration to write the HCP companion document to guide implementation of the 2019 MMWR recommendations, this session will present transition experiences of an academic medical center, a large city health department, and a state TB program, followed by an open forum with the speaker panel and participants.</i></p>	<p>Julie Higashi</p>	<p>Wendy Thanassi Melanie Swift Heidi Behm</p>



THE POWER OF PARTNERSHIPS

2020 NTC GOES VIRTUAL

<p>Wednesday, November 4, 2020 TIME: 3:00-5:00 PM EST</p>	<p>2020 Report of Verified Case of TB Training <i>During this two-hour session, participants will learn how to complete many of the new and revised items on the 2020 Report of Verified Case of TB (RVCT). The session will include an overview of 2020 RVCT items, facilitated group discussion, and opportunities for participants to exchange methods and ideas. Everyone who has a responsibility for completing the RVCT is encouraged to attend this post-NTCA RVCT training.</i></p>	<p>Julie Self</p>	<p>Robert Pratt</p>
<p>December 2020 (Date TBD) TIME: 3:00-5:00 PM EST</p>	<p>LTBI Treatment: Guidelines and Standards of Practice <i>TB prevention is an essential part of the strategy to eliminate TB. In this session, the 2020 NTCA/CDC LTBI treatment guidelines will be presented along with the NSTC companion document of current expert recommendations for the screening, testing, and treating of LTBI.</i></p>	<p>John Bernardo Charlie Crane</p>	<p>Bob Belknap Marcos Burgos</p>